The prescription has no off-ramp

Adapted from a newsletter first sent July 2, 2026.

In mid-2026, GLP-1 drugs made up roughly 20 percent of total drug spending, and most large employers were telling their benefits teams they’d hold coverage steady. The whole debate was whether to keep paying for the drug.

I think that’s the wrong debate. The one I can’t stop thinking about is what happens when the patient stops.

They do stop. Coverage lapses, side effects hit, they change jobs or they decide they’re done. And when the drug leaves, appetite comes back to a body that has quietly lost muscle along with fat. As a dietitian, this is the part that makes me wince. Rapid loss without a protein floor or any resistance work strips lean mass, and lean mass helps hold resting metabolism up. So the weight returns, but it returns as fat, on a slower engine. We spend five figures per employee and may hand them back a worse metabolic starting point than the one they began with.

Nobody owns the food side of this. The thirty grams of protein at a meal, the fiber that manages the GI side effects, the grocery list that works with a shrunken appetite, the maintenance plan for month thirteen when coverage ends: none of it is prescribed, delivered or paid for by anyone. It lives in the gap between the pharmacy and the kitchen.

For two years the Food as Medicine field has argued that it belongs in healthcare. Maybe the sharper claim is that food isn’t the alternative to the drug. It’s the off-ramp. It protects the muscle while someone is on it and catches them when they come off.

Most treatments get designed with a start. Who is supposed to design the end?

Previous
Previous

The clock is shorter than the intervention

Next
Next

Points are not a prescription